Shares of medical device companies are trading higher amid sympathy with Abbott Laboratories after that company reported better-than-expected Q2 financial results and raised its FY adjusted EPS guidance with its midpoint above estimates.

8-K filing — BAXTER INTERNATIONAL INC (BAX)

Filed: 2026-08-19 AccNo: 0001193125-26-356188 Size: 323 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Baxter International Announces Appointment Of John Rogers As CFO Effective October 1

FDA Classifies Baxter's Removal Of Certain Duo-Vent Solution Set Lots As Class I Recall Over Air Bubble Risk; Baxter Says No Serious Injuries Or Deaths Reported

Baxter International Says Anita Zielinski To Resign As Interim CFO, Effective September 15, 2026

-SEC Filing

Carlsmed Files Prospectus To Offer Up To $250M In Securities

-SEC Filing

Truist Securities Maintains Buy on Carlsmed, Raises Price Target to $20

Truist Securities analyst Richard Newitter maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $18 to $20.